3
White House | Image Credit: © Zack Frank – stock.adobe.com
United States President Donald Trump has contacted 17 pharmaceutical companies, providing them with the step-by-step process he says they must take to lower prescription drug prices in the US to the lowest price offered among other developed nations (1). This strategy, known as the most-favored-nation (MFN) price, was first detailed by the White House in an executive order signed by Trump on May 12, 2025 (2).
Conversations began after executive order
The companies receiving letters on July 31 were AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company,